Twist Bioscience Q4 revenue beats analyst expectations

What happened

Twist Bioscience said its fiscal fourth-quarter revenue beat analyst expectations, while its loss per share was $0.32. The company expects FY27 revenue to grow about 21% at the midpoint and targets positive adjusted EBITDA, meaning earnings before interest, taxes, depreciation and amortization, adjusted for certain items.

Confirmed

Global impact / market context

Revenue growth can support Twist’s ability to fund operations, but the reported quarterly loss and wider annual net loss show that growth has not yet produced overall profitability. Its FY27 outlook links expected sales expansion to a gross margin target and positive adjusted EBITDA, a measure of operating performance before certain costs.

Analyst inference

The article reports strong full-year growth in DNA Synthesis and Protein Solutions and NGS Applications, alongside more customers and gene shipments. It also reports a wider annual net loss, partly compared with a prior-year business-sale gain and FY2026 litigation costs, so sales growth alone does not show improving profitability.

Confirmed

What to watch

1. Compare future sales with the company’s FY27 revenue growth forecast; stronger revenue could support its expansion plans, while weaker sales could make that target harder to achieve. Analyst inference
2. Watch whether gross margin meets the company’s target; gross margin is the share of sales remaining after direct production costs, so it indicates how efficiently sales cover costs. Analyst inference
3. Track whether positive adjusted EBITDA is achieved and how capital spending affects cash available; spending on equipment and facilities can raise cash needs even as operations improve. Analyst inference

Evidence

• Original source link unavailable